The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
Abstract
Objective: The risk of cardiovascular disease (CVD) is increased in patients with rheumatoid arthritis (RA), most likely because of increased systemic inflammation. Prior research suggests that immunosuppressive medications may reduce the risk of CVD among RA patients. This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA. Methods: In this nested case–control study, the source cohort was derived from Medicare beneficiaries receiving a drug benefit from the state of Pennsylvania. These individuals were required to have been diagnosed as having RA on at least 2 visits and to have filled a prescription for an immunosuppressive agent. Cases were defined as those patients who were hospitalized for a cardiovascular event such as myocardial infarction or stroke, and 10 control subjects were matched to each case by age, sex, and calendar year of the index date (the time of the first cardiovascular event in each case). Current use of an immunosuppressive medication was defined as having filled a prescription for these agents within the 90 days prior to the index date. Multivariate logistic regression models that included important covariates were assessed to determine the risk of cardiovascular events associated with immunosuppressive agents and their combinations. Results: Among the study cohort, we identified 3,501 RA patients who fulfilled our eligibility criteria. During followup of this cohort, 946 patients were hospitalized for a cardiovascular event. Although the 95% confidence intervals (95% CIs) were wide in adjusted risk regression models with methotrexate (MTX) monotherapy as the reference group, biologic immunosuppressive agents showed neither protective nor deleterious effects (with biologics monotherapy, odds ratio [OR] 1.0, 95% CI 0.5–1.9; with biologics plus MTX combination therapy, OR 0.8, 95% CI 0.3–2.0; and with biologics plus other immunosuppressive agents, OR 1.2, 95% CI 0.7–2.2). Monotherapy with oral glucocorticoids was associated with an increased risk of cardiovascular events (OR 1.5, 95% CI 1.1 – 2.1), and a similar trend in the direction of risk was seen with glucocorticoid combination therapy (OR 1.3, 95% CI 0.8–2.0). Cytotoxic immunosuppressive agents other than MTX (azathioprine, cyclosporine, and leflunomide) were also associated with an increased risk of cardiovascular events (with both monotherapy and combination treatment, OR 1.8, 95% CI 1.1–3.0). Conclusion: When compared with RA patients receiving MTX monotherapy, those receiving biologic immunosuppressive agents had neither an increased nor decreased risk of experiencing a cardiovascular event, whereas use of oral glucocorticoids and cytotoxic immunosuppressive agents was associated with significant increases in the risk of cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Freiman, J. A., Chalmers, T. C., Smith, H., & Kuebler, R. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197809282991304 · Cited by 1,628
The nested case-control study in cardiology
Essebag, V., Genest, J., Suissa, S., & Pilote, L. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00512-x · Cited by 173
Cited by
Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
Micha, R., Imamura, F., Wyler von Ballmoos, M., Solomon, D. H., Hernán, M. A., Ridker, P. M., & Mozaffarian, D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.06.054 · Cited by 535
Self-citationCardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Naranjo, A., Sokka, T., Descalzo, M. A., Calvo-Alén, J., Hørslev-Petersen, K., Luukkainen, R. K., Combe, B., Burmester, G. R., Devlin, J., Ferraccioli, G., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2383 · Cited by 467
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Symmons, D. P. M., & Gabriel, S. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.75 · Cited by 406
Lindhardsen, J., Ahlehoff, O., Gislason, G. H., Madsen, O. R., Olesen, J. B., Torp-Pedersen, C., & Hansen, P. R. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143396 · Cited by 405
Greenberg, J. D., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Nasir, A., Setoguchi, S., & Solomon, D. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.129916 · Cited by 350
Self-citation
Metadata
- Authors
- Solomon, D. H., Avorn, J., Katz, J. N., Weinblatt, M. E., Setoguchi, S., Levin, R., & Schneeweiss, S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-11-29
- Volume
- 54
- Issue
- 12
- Pages
- 3790-3798
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2010964474
- Cited by
- 181
- References
- 6
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.